U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H16ClNO2S
Molecular Weight 321.8234
Optical Activity ( + )
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CLOPIDOGREL

SMILES

COC(=O)[C@]([H])(c1ccccc1Cl)N2CCc3c(ccs3)C2

InChI

InChIKey=GKTWGGQPFAXNFI-HNNXBMFYSA-N
InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1

HIDE SMILES / InChI
Clopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to inhibit blood clots in a variety of conditions such as peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Clopidogrel is sold under the name Plavix by Sanofi and Bristol-Myers Squibb. Plavix (clopidogrel bisulfate) is an inhibitor of ADP-induced platelet aggregation acting by direct inhibition of adenosine diphosphate (ADP) binding to its receptor and of the subsequent ADPmediated activation of the glycoprotein GPIIb/IIIa complex. Clopidogrel must be metabolized by CYP450 enzymes to produce the active metabolite that inhibits platelet aggregation. The active metabolite of clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet P2Y12 receptor and the subsequent ADPmediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation. This action is irreversible. Consequently, platelets exposed to clopidogrel’s active metabolite are affected for the remainder of their lifespan (about 7 to 10 days). Platelet aggregation induced by agonists other than ADP is also inhibited by blocking the amplification of platelet activation by released ADP. Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PLAVIX

Approved Use

Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows: • Recent MI, Recent Stroke or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. • Acute Coronary Syndrome -For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia. Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows: • Recent MI, Recent Stroke or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. • Acute Coronary Syndrome -For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia.

Launch Date

8.7972479E11
Primary
PLAVIX

Approved Use

Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows: • Recent MI, Recent Stroke or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. • Acute Coronary Syndrome -For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia.

Launch Date

8.7963841E11
Primary
PLAVIX

Approved Use

Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows: • Recent MI, Recent Stroke or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. • Acute Coronary Syndrome -For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia.

Launch Date

8.7972479E11
Preventing
PLAVIX

Approved Use

Plavix (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows: • Recent MI, Recent Stroke or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, Plavix has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. • Acute Coronary Syndrome -For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/nonQ-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia.

Launch Date

8.7972479E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1500 pg/mL
75 mg 1 times / day multiple, oral
dose: 75 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
15800 pg/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
2520 pg/mL
75 mg 1 times / day multiple, oral
dose: 75 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
4600 pg/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
0.521 ng/mL
75 mg single, oral
dose: 75 mg
route of administration: oral
experiment type: single
co-administered:
CLOPIDOGREL plasma
Homo sapiens
population: healthy
age:
sex:
food status:
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
3130 pg × h/mL
75 mg 1 times / day multiple, oral
dose: 75 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
50600 pg × h/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
7440 pg × h/mL
75 mg 1 times / day multiple, oral
dose: 75 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
9890 pg × h/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
0.767 ng*h/mL
75 mg single, oral
dose: 75 mg
route of administration: oral
experiment type: single
co-administered:
CLOPIDOGREL plasma
Homo sapiens
population: healthy
age:
sex:
food status:
1.09 ng*h/mL
75 mg single, oral
dose: 75 mg
route of administration: oral
experiment type: single
co-administered:
CLOPIDOGREL plasma
Homo sapiens
population: healthy
age:
sex:
food status:
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8.5 h
75 mg 1 times / day multiple, oral
dose: 75 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
5.4 h
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
7.4 h
75 mg 1 times / day multiple, oral
dose: 75 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
7.9 h
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
2%
unknown, unknown
CLOPIDOGREL BISULFATE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
600 mg 1 times / day multiple, oral (starting)
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, 20-45 years
n = 27
Health Status: healthy
Age Group: 20-45 years
Sex: M
Population Size: 27
Sources:
Other AEs: Uric acid abnormal...
Other AEs:
Uric acid abnormal (5 patients)
Sources:
1650 mg single, oral
Overdose
Dose: 1650 mg
Route: oral
Route: single
Dose: 1650 mg
Co-administed with::
phenytoin sodium(1400 mg; single)
simvastatin(120 mg; single)
Sources:
unknown, 49 years
n = 1
Health Status: unknown
Age Group: 49 years
Sex: M
Population Size: 1
Sources:
600 mg 1 times / day multiple, oral (starting)
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 59 years
n = 1
Health Status: unhealthy
Age Group: 59 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Transaminases increased, Fever...
AEs leading to
discontinuation/dose reduction:
Transaminases increased (1 patient)
Fever (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Uric acid abnormal 5 patients
600 mg 1 times / day multiple, oral (starting)
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
healthy, 20-45 years
n = 27
Health Status: healthy
Age Group: 20-45 years
Sex: M
Population Size: 27
Sources:
Fever 1 patient
Disc. AE
600 mg 1 times / day multiple, oral (starting)
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 59 years
n = 1
Health Status: unhealthy
Age Group: 59 years
Sex: F
Population Size: 1
Sources:
Transaminases increased 1 patient
Disc. AE
600 mg 1 times / day multiple, oral (starting)
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
unhealthy, 59 years
n = 1
Health Status: unhealthy
Age Group: 59 years
Sex: F
Population Size: 1
Sources:
PubMed

PubMed

TitleDatePubMed
Drug-induced thrombotic microangiopathy: incidence, prevention and management.
2001
Current oral antiplatelet agents to prevent atherothrombosis.
2001
Benefit of ADP receptor antagonists in atherothrombotic patients: new evidence.
2001
The use of antiplatelet agents in acute cardiac care.
2001 Apr
Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk.
2001 Apr
Aspirin in patients with coronary artery disease: is it simply irresistible?
2001 Apr
[Optimal platelet inhibition therapy in unstable angina pectoris and after coronary interventions].
2001 Apr
[Pathophysiology of platelet activation and pharmacology of GPIIb/IIIa inhibitors].
2001 Apr
Regular or "super-aspirins"? A review of thienopyridines or aspirin to prevent stroke.
2001 Apr
Ultrasound guided percutaneous thrombin injection of iatrogenic femoral artery pseudoaneurysms after coronary angiography and intervention.
2001 Apr
Management of neurological complications of carotid artery stenting.
2001 Aug
Radiation-induced glomerular thrombus formation and nephropathy are not prevented by the ADP receptor antagonist clopidogrel.
2001 Aug 1
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
2001 Aug 18
Clopidogrel in invasive management of non-ST-elevation ACS.
2001 Aug 18
Bench to bedside: the development of rapamycin and its application to stent restenosis.
2001 Aug 21
Severe hypersensitivity associated with clopidogrel.
2001 Aug 21
Antithrombotic drugs for older subjects. Guidelines formulated jointly by the Italian Societies of Haemostasis and Thrombosis (SISET) and of Gerontology and Geriatrics (SIGG).
2001 Feb
Thrombolysis and antithrombotic therapy for coronary artery disease.
2001 Feb
Fatal aplastic anaemia associated with clopidogrel.
2001 Feb 10
Current perspectives on British use of adjunctive therapies during coronary interventions.
2001 Jul
The role of adenosine 5'-diphosphate receptor blockade in patients with cardiovascular disease.
2001 Jul
Multiple intracranial aneurysms as delayed complications of an atrial myxoma: case report.
2001 Jul
Extensive thrombus prior to elective percutaneous coronary intervention.
2001 Jul
Diffuse alveolar hemorrhage after clopidogrel use.
2001 Jul
Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population.
2001 Jul 31
The P2Y12 receptor as a therapeutic target in cardiovascular disease.
2001 Jun
[Toxic skin reaction to clopidogrel].
2001 Jun
Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs.
2001 Jun
Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: analysis of 5,678 patients with a four-week ticlopidine regimen.
2001 Jun 15
Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
2001 Jun 21
[Acute coronary syndromes: an update. I. Pathogenesis and drug therapy].
2001 Mar
[Acute coronary syndromes: an update. II. Coronary revascularization and risk stratification].
2001 Mar
[Pharmacy clinics. Medication of the month. Clopidogrel (Plavix)].
2001 Mar
Activation of Gi-coupled receptors releases a tonic state of inhibited platelet aggregation.
2001 Mar
Initial experience with a newer generation coronary stent.
2001 Mar
[Therapeutic aspects of cerebral ischemia].
2001 Mar 10
[Cost effectiveness of clopidogrel in secondary cardiovascular prevention: a cost-effectiveness analysis based on the Caprie Study].
2001 Mar 29
What is the optimal medical management of ischemic heart failure?
2001 Mar-Apr
[Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery].
2001 May
The inhibition of oxygen radical release from human neutrophils by resting platelets is reversed by administration of acetylsalicylic acid or clopidogrel.
2001 May
New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines.
2001 May
Orbofiban: an orally active GPIIb/IIIa platelet receptor antagonist.
2001 May
Edge stenosis after intracoronary radiotherapy: angiographic, intravascular, and histological findings.
2001 May 1
Methods and models to evaluate shear-dependent and surface reactivity-dependent antithrombotic efficacy.
2001 Nov 1
Antiplatelet agents for secondary prevention of ischemic stroke.
2001 Oct
Prevention of venous graft sclerosis with clopidogrel and aspirin combined with a mesh tubing in a dog model of arteriovenous bypass grafting.
2001 Oct
Thrombotic thrombocytopenic purpura associated with clopidogrel administration: case report and brief review.
2001 Sep
Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro.
2001 Sep
Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers.
2001 Sep
Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein.
2001 Sep 15
Patents

Sample Use Guides

Recent MI, Recent Stroke, or Established Peripheral Arterial Disease The recommended daily dose of is 75 mg once daily.
Route of Administration: Oral
Incubation of human washed platelets with clopidogrel resulted in a time- (maximum effects after 30 min) and concentration-dependent (IC50 1.9+/-0.3 uM) inhibition of ADP (6 uM)-induced platelet aggregation. Clopidogrel (30 uM) did not inhibit collagen (2.5 ug ml(-1))-, U46619 (1 uM)- or thrombin (0.1 u ml(-1))-induced platelet aggregation.
Name Type Language
CLOPIDOGREL
EMA EPAR   HSDB   INN   MI   VANDF   WHO-DD  
INN  
Official Name English
CLOPIDOGREL [INN]
Common Name English
(S)-METHYL .ALPHA.-(4,5,6,7-TETRAHYDROTHIENO(3,2-C)PYRIDIN-5-YL)-.ALPHA.-(O-CHLOROPHENYL)ACETATE
Common Name English
SR-25990
Code English
CLOPIDOGREL [HSDB]
Common Name English
NSC-758613
Code English
THROMBO
Common Name English
(+)-(S)-CLOPIDOGREL
Common Name English
SR 25990
Code English
CLOPIDOGREL [VANDF]
Common Name English
R 130964
Code English
METHYL 2-(2-CHLOROPHENYL)-2-(4,5,6,7-TETRAHYDROTHIENO(3,2-C)PYRIDIN-5-YL)ACETATE
Systematic Name English
ZYLLT
Common Name English
CLOPIDOGREL [EMA EPAR]
Common Name English
CLOPIDOGREL [MI]
Common Name English
CLOPIDOGREL [WHO-DD]
Common Name English
R-130964
Code English
Classification Tree Code System Code
NDF-RT N0000008832
Created by admin on Fri Jun 25 21:53:34 UTC 2021 , Edited by admin on Fri Jun 25 21:53:34 UTC 2021
WHO-VATC QB01AC04
Created by admin on Fri Jun 25 21:53:34 UTC 2021 , Edited by admin on Fri Jun 25 21:53:34 UTC 2021
WHO-ATC B01AC04
Created by admin on Fri Jun 25 21:53:34 UTC 2021 , Edited by admin on Fri Jun 25 21:53:34 UTC 2021
NCI_THESAURUS C80483
Created by admin on Fri Jun 25 21:53:34 UTC 2021 , Edited by admin on Fri Jun 25 21:53:34 UTC 2021
EMA ASSESSMENT REPORTS CLOPIDOGREL ACINO (AUTHORIZED:ACUTE CORONARY SYNDROME)
Created by admin on Fri Jun 25 21:53:34 UTC 2021 , Edited by admin on Fri Jun 25 21:53:34 UTC 2021
NDF-RT N0000008832
Created by admin on Fri Jun 25 21:53:34 UTC 2021 , Edited by admin on Fri Jun 25 21:53:34 UTC 2021
NDF-RT N0000182142
Created by admin on Fri Jun 25 21:53:34 UTC 2021 , Edited by admin on Fri Jun 25 21:53:34 UTC 2021
NDF-RT N0000175578
Created by admin on Fri Jun 25 21:53:34 UTC 2021 , Edited by admin on Fri Jun 25 21:53:34 UTC 2021
LIVERTOX 226
Created by admin on Fri Jun 25 21:53:34 UTC 2021 , Edited by admin on Fri Jun 25 21:53:34 UTC 2021
EMA ASSESSMENT REPORTS CLOPIDOGREL ACINO (AUTHORIZED: MYOCARDIAL INFARCTION)
Created by admin on Fri Jun 25 21:53:34 UTC 2021 , Edited by admin on Fri Jun 25 21:53:34 UTC 2021
Code System Code Type Description
ChEMBL
CHEMBL1771
Created by admin on Fri Jun 25 21:53:34 UTC 2021 , Edited by admin on Fri Jun 25 21:53:34 UTC 2021
PRIMARY
MESH
C055162
Created by admin on Fri Jun 25 21:53:34 UTC 2021 , Edited by admin on Fri Jun 25 21:53:34 UTC 2021
PRIMARY
DRUG BANK
DB00758
Created by admin on Fri Jun 25 21:53:34 UTC 2021 , Edited by admin on Fri Jun 25 21:53:34 UTC 2021
PRIMARY
HSDB
7430
Created by admin on Fri Jun 25 21:53:34 UTC 2021 , Edited by admin on Fri Jun 25 21:53:34 UTC 2021
PRIMARY
MERCK INDEX
M3655
Created by admin on Fri Jun 25 21:53:34 UTC 2021 , Edited by admin on Fri Jun 25 21:53:34 UTC 2021
PRIMARY Merck Index
CAS
113665-84-2
Created by admin on Fri Jun 25 21:53:34 UTC 2021 , Edited by admin on Fri Jun 25 21:53:34 UTC 2021
PRIMARY
WIKIPEDIA
CLOPIDOGREL
Created by admin on Fri Jun 25 21:53:34 UTC 2021 , Edited by admin on Fri Jun 25 21:53:34 UTC 2021
PRIMARY
INN
5908
Created by admin on Fri Jun 25 21:53:34 UTC 2021 , Edited by admin on Fri Jun 25 21:53:34 UTC 2021
PRIMARY
NDF-RT
N0000182143
Created by admin on Fri Jun 25 21:53:34 UTC 2021 , Edited by admin on Fri Jun 25 21:53:34 UTC 2021
PRIMARY P2Y12 Receptor Antagonists [MoA]
IUPHAR
7150
Created by admin on Fri Jun 25 21:53:34 UTC 2021 , Edited by admin on Fri Jun 25 21:53:34 UTC 2021
PRIMARY
EVMPD
SUB13395MIG
Created by admin on Fri Jun 25 21:53:34 UTC 2021 , Edited by admin on Fri Jun 25 21:53:34 UTC 2021
PRIMARY
EPA CompTox
113665-84-2
Created by admin on Fri Jun 25 21:53:34 UTC 2021 , Edited by admin on Fri Jun 25 21:53:34 UTC 2021
PRIMARY
DRUG CENTRAL
708
Created by admin on Fri Jun 25 21:53:34 UTC 2021 , Edited by admin on Fri Jun 25 21:53:34 UTC 2021
PRIMARY
LACTMED
Clopidogrel
Created by admin on Fri Jun 25 21:53:34 UTC 2021 , Edited by admin on Fri Jun 25 21:53:34 UTC 2021
PRIMARY
FDA UNII
A74586SNO7
Created by admin on Fri Jun 25 21:53:34 UTC 2021 , Edited by admin on Fri Jun 25 21:53:34 UTC 2021
PRIMARY
RXCUI
32968
Created by admin on Fri Jun 25 21:53:34 UTC 2021 , Edited by admin on Fri Jun 25 21:53:34 UTC 2021
PRIMARY RxNorm
NCI_THESAURUS
C61686
Created by admin on Fri Jun 25 21:53:34 UTC 2021 , Edited by admin on Fri Jun 25 21:53:34 UTC 2021
PRIMARY
PUBCHEM
60606
Created by admin on Fri Jun 25 21:53:34 UTC 2021 , Edited by admin on Fri Jun 25 21:53:34 UTC 2021
PRIMARY